### Recommended Immunization Schedule for Persons Aged 0–6 Years—UNITED STATES • 2008

For those who fall behind or start late, see the catch-up schedule

<table>
<thead>
<tr>
<th>Vaccine ▼</th>
<th>Age ▼</th>
<th>Birth</th>
<th>1 month</th>
<th>2 months</th>
<th>4 months</th>
<th>6 months</th>
<th>12 months</th>
<th>15 months</th>
<th>18 months</th>
<th>19–23 months</th>
<th>2–3 years</th>
<th>4–6 years</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hepatitis B</td>
<td>HepB</td>
<td>HepB</td>
<td>HepB</td>
<td>HepB</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rotavirus</td>
<td>Rota</td>
<td>Rota</td>
<td>Rota</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Diphtheria, Tetanus, Pertussis</td>
<td>DTaP</td>
<td>DTaP</td>
<td>DTaP</td>
<td>DTaP</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Haemophilus influenzae type b</td>
<td>Hib</td>
<td>Hib</td>
<td>Hib</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pneumococcal</td>
<td>PCV</td>
<td>PCV</td>
<td>PCV</td>
<td>PCV</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inactivated Poliovirus</td>
<td>IPV</td>
<td>IPV</td>
<td>IPV</td>
<td>IPV</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Influenza</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Measles, Mumps, Rubella</td>
<td>MMR</td>
<td>MMR</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Varicella</td>
<td>Varicella</td>
<td>Varicella</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hepatitis A</td>
<td>HepA (2 doses)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Meningococcal</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

This schedule indicates the recommended ages for routine administration of currently licensed childhood vaccines, as of December 1, 2007, for children aged 0 through 6 years. Additional information is available at [www.cdc.gov/vaccines/recs/schedules](http://www.cdc.gov/vaccines/recs/schedules). Any dose not administered at the recommended age should be administered at any subsequent visit, when indicated and feasible. Additional vaccines may be licensed and recommended during the year. Licensed combination vaccines may be used whenever any components of the combination are indicated and other components of the vaccine are not contraindicated and if approved by the Food and Drug Administration for that dose of the series. Providers should consult the respective Advisory Committee on Immunization Practices statement for detailed recommendations, including for high-risk conditions: [http://www.cdc.gov/vaccines/pubs/ACIP-list.htm](http://www.cdc.gov/vaccines/pubs/ACIP-list.htm). Clinically significant adverse events that follow immunization should be reported to the Vaccine Adverse Event Reporting System (VAERS). Guidance about how to obtain and complete a VAERS form is available at [www.vaers.hhs.gov](http://www.vaers.hhs.gov) or by telephone, 800-822-7967.

#### 1. Hepatitis B vaccine (HepB). (Minimum age: birth)

**At birth:**
- Administer monovalent HepB to all newborns prior to hospital discharge.
- If mother is hepatitis B surface antigen (HBsAg) positive, administer HepB and 0.5 mL of hepatitis B immune globulin (HBIG) within 12 hours of birth.
- If mother’s HBsAg status is unknown, administer HepB within 12 hours of birth. Determine the HBsAg status as soon as possible and if HBsAg positive, administer HBIG (no later than age 1 week).
- If mother is HBsAg negative, the birth dose can be delayed, in rare cases, with a provider’s order and a copy of the mother’s negative HBsAg laboratory report in the infant’s medical record.

**After the birth dose:**
- The HepB series should be completed with either monovalent HepB or a combination vaccine containing HepB. The second dose should be administered at age 1–2 months. The final dose should be administered no earlier than age 24 weeks. Infants born to HBsAg-positive mothers should be tested for HBsAg and antibody to HBsAg after completion of at least 3 doses of a licensed HepB series, at age 9–18 months (generally at the next well-child visit).
- 4-month dose:
  - It is permissible to administer 4 doses of HepB when combination vaccines are administered after the birth dose. If monovalent HepB is used for doses after the birth dose, a dose at age 4 months is not needed.

#### 2. Rotavirus vaccine (Rota). (Minimum age: 6 weeks)

- Administer the first dose at age 6–12 weeks.
- Do not start the series later than age 12 weeks.
- Administer the final dose in the series by age 32 weeks. Do not administer any dose later than age 32 weeks.
- Data on safety and efficacy outside of these age ranges are insufficient.

#### 3. Diphtheria and tetanus toxoids and acellular pertussis vaccine (DTaP). (Minimum age: 6 weeks)

- The fourth dose of DTaP may be administered as early as age 12 months, provided 6 months have elapsed since the third dose.
- Administer the final dose in the series at age 4–6 years.

#### 4. Haemophilus influenzae type b conjugate vaccine (Hib). (Minimum age: 6 weeks)

- If PRP-OMP (PedvaxHIB® or ComVax® [Merck]) is administered at ages 2 and 4 months, a dose at age 6 months is not required.
- dTw Hib® (DTaP/Hib) combination products should not be used for primary immunization but can be used as boosters following any Hib vaccine in children age 12 months or older.

#### 5. Pneumococcal vaccine. (Minimum age: 6 weeks for pneumococcal conjugate vaccine [PCV]; 2 years for pneumococcal polysaccharide vaccine [PPV])

- Administer one dose of PCV to all healthy children aged 24–59 months having any incomplete schedule.
- Administer PPV to children aged 2 years and older with underlying medical conditions.

#### 6. Influenza vaccine. (Minimum age: 6 months for trivalent inactivated influenza vaccine [TIV]; 2 years for live, attenuated influenza vaccine [LAIV])

- Administer annually to children aged 6–59 months and to all eligible close contacts of children aged 0–59 months.
- Administer annually to children 5 years of age and older with certain risk factors, to other persons (including household members) in close contact with persons in groups at higher risk, and to any child whose parents request vaccination.
- For healthy persons (those who do not have underlying medical conditions that predispose them to influenza complications) ages 2–49 years, either LAIV or TIV may be used.
- Children receiving TIV should receive 0.25 mL if age 6–35 months or 0.5 mL if age 3 years or older.
- Administer 2 doses (separated by 4 weeks or longer) to children younger than 9 years who are receiving influenza vaccine for the first time or who were vaccinated for the first time last season but only received one dose.

#### 7. Measles, mumps, and rubella vaccine (MMR). (Minimum age: 12 months)

- Administer the second dose of MMR at age 4–6 years. MMR may be administered before age 4–6 years, provided 4 weeks or more have elapsed since the first dose.

#### 8. Varicella vaccine. (Minimum age: 12 months)

- Administer second dose at age 4–6 years; may be administered 3 months or more after first dose.
- Do not repeat second dose if administered 28 days or more after first dose.

#### 9. Hepatitis A vaccine (HepA). (Minimum age: 12 months)

- Administer to all children aged 1 year (i.e., aged 12–23 months). Administer the 2 doses in the series at least 6 months apart.
- Children not fully vaccinated by age 2 years can be vaccinated at subsequent visits.
- HepA is recommended for certain other groups of children, including in areas where vaccination programs target older children.

#### 10. Meningococcal vaccine. (Minimum age: 2 years for meningococcal conjugate vaccine [MCV4] and for meningococcal polysaccharide vaccine [MPSV4])

- Administer MCV4 to children aged 2–10 years with terminal complement deficiencies or anatomic or functional asplenia and certain other high-risk groups. MPSV4 is also acceptable.
- Administer MCV4 to persons who received MPSV4 3 or more years previously and remain at increased risk for meningococcal disease.
**Recommended Immunization Schedule for Persons Aged 7–18 Years—UNITED STATES • 2008**

For those who fall behind or start late, see the green bars and the catch-up schedule

<table>
<thead>
<tr>
<th>Vaccine ▼</th>
<th>Age ▶</th>
<th>7–10 years</th>
<th>11–12 years</th>
<th>13–18 years</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diphtheria, Tetanus, Pertussis¹</td>
<td>see footnote 1</td>
<td>Tdap</td>
<td>Tdap</td>
<td></td>
</tr>
<tr>
<td>Human Papillomavirus²</td>
<td>see footnote 2</td>
<td>HPV (3 doses)</td>
<td>HPV Series</td>
<td></td>
</tr>
<tr>
<td>Meningococcal³</td>
<td>MCV4</td>
<td>MCV4</td>
<td>MCV4</td>
<td></td>
</tr>
<tr>
<td>Pneumococcal⁴</td>
<td>PPV</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Influenza⁵</td>
<td>Influenza (Yearly)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hepatitis A⁶</td>
<td>HepA Series</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hepatitis B⁷</td>
<td>HepB Series</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inactivated Poliovirus⁸</td>
<td>IPV Series</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Measles, Mumps, Rubella⁹</td>
<td>MMR Series</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Varicella¹⁰</td>
<td>Varicella Series</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

This schedule indicates the recommended ages for routine administration of currently licensed childhood vaccines, as of December 1, 2007, for children aged 7–18 years. Additional information is available at [www.cdc.gov/vaccines/recs/schedules](http://www.cdc.gov/vaccines/recs/schedules). Any dose not administered at the recommended age should be administered at any subsequent visit, when indicated and feasible. Additional vaccines may be licensed and recommended during the year. Licensed combination vaccines may be used whenever any components of the combination are indicated and other components of the vaccine are not contraindicated and if approved by the Food and Drug Administration for that dose of the series. Providers should consult the respective Advisory Committee on Immunization Practices statement for detailed recommendations, including for high risk conditions: [http://www.cdc.gov/vaccines/pubs/ACIP-list.htm](http://www.cdc.gov/vaccines/pubs/ACIP-list.htm). Clinically significant adverse events that follow immunization should be reported to the [VacQuarde Adverse Event Reporting System (VAERS)](http://www.vaers.hhs.gov). Guidance about how to obtain and complete a VAERS form is available at [www.vaers.hhs.gov](http://www.vaers.hhs.gov) or by telephone, 800-822-7967.

1. **Tetanus and diphtheria toxoids and acellular pertussis vaccine (Tdap).** *(Minimum age: 10 years for BOOSTRIX® and 11 years for ADACEL ™)*
   - Administer at age 11–12 years for those who have completed the recommended childhood DTP/DTaP vaccination series and have not received a tetanus and diphtheria toxoids (Td) booster dose.
   - 13–18-year-olds who missed the 11–12 year Tdap or received Td only are encouraged to receive one dose of Tdap 5 years after the last Td/DTaP dose.

2. **Human papillomavirus vaccine (HPV).** *(Minimum age: 9 years)*
   - Administer the first dose of the HPV vaccine series to females at age 11–12 years.
   - Administer the second dose 2 months after the first dose and the third dose 6 months after the first dose.
   - Administer the HPV vaccine series to females at age 13–18 years if not previously vaccinated.

3. **Meningococcal vaccine.**
   - Administer MCV4 at age 11–12 years and at age 13–18 years if not previously vaccinated. MPSV4 is an acceptable alternative.
   - Administer MCV4 to previously unvaccinated college freshmen living in dormitories.
   - MCV4 is recommended for children aged 2–10 years with terminal complement deficiencies or anatomic or functional asplenia and certain other high-risk groups.
   - Persons who received MPSV4 3 or more years previously and remain at increased risk for meningococcal disease should be vaccinated with MCV4.

4. **Pneumococcal polysaccharide vaccine (PPV).**
   - Administer PPV to certain high-risk groups.

5. **Influenza vaccine.**
   - Administer annually to all close contacts of children aged 0–59 months.
   - Administer annually to persons with certain risk factors, health-care workers, and other persons (including household members) in close contact with persons in groups at higher risk.
   - Administer 2 doses (separated by 4 weeks or longer) to children younger than 9 years who are receiving influenza vaccine for the first time or who were vaccinated for the first time last season but only received one dose.
   - For healthy nonpregnant persons (those who do not have underlying medical conditions that predispose them to influenza complications) ages 2–49 years, either LAIV or TIV may be used.

6. **Hepatitis A vaccine (HepA).**
   - Administer the 2 doses in the series at least 6 months apart.
   - HepA is recommended for certain other groups of children, including areas where vaccination programs target older children.

7. **Hepatitis B vaccine (HepB).**
   - Administer the 3-dose series to those who were not previously vaccinated.
   - A 2-dose series of Recombivax HB® is licensed for children aged 11–15 years.

8. **Inactivated poliovirus vaccine (IPV).**
   - For children who received an all-IPV or all-oral poliovirus (OPV) series, a fourth dose is not necessary if the third dose was administered at age 4 years or older.
   - If both OPV and IPV were administered as part of a series, a total of 4 doses should be administered, regardless of the child’s current age.

9. **Measles, mumps, and rubella vaccine (MMR).**
   - If not previously vaccinated, administer 2 doses of MMR during any visit, with 4 or more weeks between the doses.

10. **Varicella vaccine.**
    - Administer 2 doses of varicella vaccine to persons younger than 13 years of age at least 3 months apart. Do not repeat the second dose if administered 28 or more days following the first dose.
    - Administer 2 doses of varicella vaccine to persons aged 13 years or older at least 4 weeks apart.

The Recommended Immunization Schedules for Persons Aged 0–18 Years are approved by the Advisory Committee on Immunization Practices ([www.cdc.gov/vaccines/recs/acip](http://www.cdc.gov/vaccines/recs/acip)), the American Academy of Pediatrics ([http://www.aap.org](http://www.aap.org)), and the American Academy of Family Physicians ([http://www.aafp.org](http://www.aafp.org)).
## Catch-up Immunization Schedule for Persons Aged 4 Months–18 Years Who Start Late or Who Are More Than 1 Month Behind

The table below provides catch-up schedules and minimum intervals between doses for children whose vaccinations have been delayed. A vaccine series does not need to be restarted, regardless of the time that has elapsed between doses. Use the section appropriate for the child’s age.

### CATCH-UP SCHEDULE FOR PERSONS AGED 4 MONTHS–6 YEARS

<table>
<thead>
<tr>
<th>Vaccine</th>
<th>Minimum Age for Dose 1</th>
<th>Minimum Interval Between Doses</th>
<th>Minimum Interval Between Doses</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Dose 1 to Dose 2</td>
<td>Dose 2 to Dose 3</td>
</tr>
<tr>
<td><strong>Hepatitis B</strong></td>
<td>Birth</td>
<td>4 weeks</td>
<td>8 weeks (and 16 weeks after first dose)</td>
</tr>
<tr>
<td><strong>Rotavirus</strong></td>
<td></td>
<td>6 wks</td>
<td>4 weeks</td>
</tr>
<tr>
<td><strong>Diphtheria, Tetanus, Pertussis</strong></td>
<td>6 wks</td>
<td>8 weeks (as final dose)</td>
<td>4 weeks</td>
</tr>
<tr>
<td><strong>Inactivated Poliovirus</strong></td>
<td>6 wks</td>
<td>8 weeks (as final dose)</td>
<td>8 weeks (as final dose)</td>
</tr>
<tr>
<td><strong>Haemophilus influenzae type b</strong></td>
<td>6 wks</td>
<td>4 weeks</td>
<td>4 weeks</td>
</tr>
<tr>
<td><strong>Pneumococcal</strong></td>
<td>6 wks</td>
<td>4 weeks</td>
<td>4 weeks</td>
</tr>
<tr>
<td><strong>Inactivated Poliovirus</strong></td>
<td>6 wks</td>
<td>4 weeks</td>
<td>8 weeks (as final dose)</td>
</tr>
<tr>
<td><strong>Measles, Mumps, Rubella</strong></td>
<td>12 mos</td>
<td>4 weeks</td>
<td>8 weeks (as final dose)</td>
</tr>
<tr>
<td><strong>Varicella</strong></td>
<td>12 mos</td>
<td>4 weeks</td>
<td>4 weeks</td>
</tr>
<tr>
<td><strong>Hepatitis A</strong></td>
<td>12 mos</td>
<td>4 weeks</td>
<td>6 months</td>
</tr>
</tbody>
</table>

### CATCH-UP SCHEDULE FOR PERSONS AGED 7–18 YEARS

<table>
<thead>
<tr>
<th>Vaccine</th>
<th>Minimum Age for Dose 1</th>
<th>Minimum Interval Between Doses</th>
<th>Minimum Interval Between Doses</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Tetanus, Diphtheria/ Tetanus, Diphtheria, Pertussis</strong></td>
<td>7 yrs&lt;sup&gt;10&lt;/sup&gt;</td>
<td>4 weeks</td>
<td>4 weeks</td>
</tr>
<tr>
<td><strong>Human Papillomavirus</strong></td>
<td>9 yrs</td>
<td>4 weeks</td>
<td>8 weeks (as final dose)</td>
</tr>
<tr>
<td><strong>Hepatitis A</strong></td>
<td>Birth</td>
<td>4 weeks</td>
<td>8 weeks (as final dose)</td>
</tr>
<tr>
<td><strong>Inactivated Poliovirus</strong></td>
<td>6 wks</td>
<td>4 weeks</td>
<td>4 weeks</td>
</tr>
<tr>
<td><strong>Measles, Mumps, Rubella</strong></td>
<td>12 mos</td>
<td>4 weeks</td>
<td>8 weeks (as final dose)</td>
</tr>
<tr>
<td><strong>Varicella</strong></td>
<td>12 mos</td>
<td>4 weeks</td>
<td>4 weeks</td>
</tr>
</tbody>
</table>

1. Hepatitis B vaccine (HepB).
   - Administer the 3-dose series to those who were not previously vaccinated.
   - A 2-dose series of Recombivax HB® is licensed for children aged 11–15 years.

2. Rotavirus vaccine (RotA).
   - Do not start the series later than age 12 weeks.
   - Administer the first dose in the series by age 32 weeks.
   - Do not administer a dose later than 32 weeks.
   - Data on safety and efficacy outside of these age ranges are insufficient.

3. Diphtheria and tetanus toxoids and acellular pertussis vaccine (DTaP).
   - The fifth dose is not necessary if the fourth dose was administered at age 4 years or older.
   - DTaP is not indicated for persons aged 7 years or older.

4. Haemophilus influenzae type b conjugate vaccine (Hib).
   - Vaccine is not generally recommended for children aged 5 years or younger.
   - If current age is younger than 12 months and the first 2 doses were PRP-OMP (PedvaxHIB® or Comvax® [Merck]), the third (and final) dose should be administered at age 12–15 months and at least 8 weeks after the second dose.
   - If first dose was administered at age 7–11 months, administer 2 doses separated by 4 weeks plus a booster at age 12–15 months.

5. Pneumococcal conjugate vaccine (PCV).
   - Administer one dose of PCV to all healthy children aged 24–59 months having an incomplete schedule.
   - For children with underlying medical conditions, administer 2 doses of PCV at least 8 weeks if previously received less than 3 doses, or 1 dose of PCV if previously received 3 doses.

6. Inactivated poliovirus vaccine (IPV).
   - For children who received an all-IPV or all-oral poliovirus (OPV) series, a fourth dose is not necessary if third dose was administered at age 4 years or older.
   - If both OPV and IPV were administered as part of a series, a total of 4 doses should be administered, regardless of the child's current age.
   - IPV is not routinely recommended for persons aged 18 years and older.

7. Measles, mumps, and rubella vaccine (MMR).
   - The second dose of MMR is recommended routinely at age 4–6 years but may be administered earlier if desired.
   - If not previously vaccinated, administer 2 doses of MMR at any visit with 4 or more weeks between the doses.

8. Varicella vaccine.
   - The second dose of varicella vaccine is recommended routinely at age 4–6 years but may be administered earlier if desired.
   - Do not repeat the second dose in persons younger than 13 years of age if administered 28 or more days after the first dose.

9. Hepatitis A vaccine (HepA).
   - HepA is recommended for certain groups of children, including in areas where vaccination programs target older children. See MMWR 2006;55(No. RR-7):1–23.

10. Tetanus and diphtheria toxoids vaccine (Td) and tetanus and diphtheria toxoids and acellular pertussis vaccine (Tdap).
    - Tdap should be substituted for a single dose of Td in the primary catch-up series or as a booster if age appropriate; use Td for other doses.
    - A 5-year interval from the last Td dose is encouraged when Tdap is used as a booster dose. A booster (fourth) dose is needed if any of the previous doses were administered at younger than 12 months of age. Refer to ACIP recommendations for further information. See MMWR 2006;55(No. RR-3).

11. Human papillomavirus vaccine (HPV).
    - Administer the HPV vaccine series to females at age 13–18 years if not previously vaccinated.

---

Information about reporting reactions after immunization is available online at [http://www.vaers.hhs.gov](http://www.vaers.hhs.gov) or by telephone via the 24-hour national toll-free information line 800-822-7967. Suspected cases of vaccine-preventable diseases should be reported to the state or local health department. Additional information, including precautions and contraindications for immunization, is available from the National Center for Immunization and Respiratory Diseases at [http://www.cdc.gov/vaccines](http://www.cdc.gov/vaccines) or telephone, 800-CDC-INFO (800-232-4636).
### The United Kingdom Childhood Vaccination Schedule

<table>
<thead>
<tr>
<th>Abbreviations</th>
<th>DTaP</th>
<th>IPV</th>
<th>Hib</th>
<th>MenC</th>
<th>PCV7</th>
<th>MMR</th>
<th>BCG</th>
<th>Td</th>
</tr>
</thead>
<tbody>
<tr>
<td>At birth</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Yes</td>
</tr>
<tr>
<td>2 months</td>
<td>Yes¹</td>
<td>Yes¹</td>
<td>Yes¹</td>
<td></td>
<td>Yes</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3 months</td>
<td>Yes¹</td>
<td>Yes¹</td>
<td>Yes¹</td>
<td>Yes</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4 months</td>
<td>Yes¹</td>
<td>Yes¹</td>
<td>Yes¹</td>
<td>Yes</td>
<td>Yes</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Around 12 months</td>
<td></td>
<td>Yes²</td>
<td></td>
<td></td>
<td>Yes²</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Around 13 months</td>
<td></td>
<td>Yes</td>
<td></td>
<td></td>
<td>Yes</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3 years 4 months-5 years</td>
<td>Yes³</td>
<td>Yes³</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Yes</td>
<td></td>
</tr>
<tr>
<td>13-18 years</td>
<td>Yes⁴</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Yes⁴</td>
</tr>
</tbody>
</table>

The United Kingdom Childhood Vaccination Schedule as on 10 January 2007

1. DTaP, IPV and Hib are given as a combined vaccine.
2. Hib and MenC are given as a combined vaccine.
3. DTaP (or dTaP) and IPV are given as a combined vaccine.
4. Td and IPV are given as a combined vaccine.
5. In addition to the recommendations for targeted and high risk group infants to receive BCG (see below 6) the BCG vaccination policy extends to:
   - Previously unvaccinated new immigrants from high prevalence countries for TB.
   - Children who after screening for TB risk factors and tested and result negative using the Mantoux test.
6. BCG is recommended to all:
   - Infants living in areas where the incidence of TB is 40/100,000 or greater.
   - Infants whose parents or grandparents were born in a country with a TB incidence of 40/100,000 or higher.
**Additional comments**

Human papillomavirus (HPV) vaccination programme for all 12- to 13-year-old girls is planned to start in 2008, with a catch-up campaign for girls up to 18 years old.[1]

Hepatitis B vaccination is recommended for babies born to mothers who are chronic carriers of hepatitis B virus or to mothers who have had acute hepatitis B during pregnancy plus their close family members. It is also recommended for those likely to be in close contact with carriers.

**Historic changes**


2005: BCG vaccination programme - As from July 2005 an improved targeted neonatal and other at risk based programme replaced the current schools’ programme for older children.

2006: Pneumococcal vaccine added to the childhood vaccination schedule.

2006: Hib-MenC booster to be given at around 12 months added to the childhood vaccination schedule.

This summary chart is adapted from the national immunisation schedule for the UK based upon advice from the UK Joint Committee for Vaccination and Immunisation (JCVI). The latest information on vaccines and vaccination procedures for all the vaccine preventable infectious diseases that may occur in the UK is available at this [website](http://www.ssi.dk/graphics/euvac/vaccination/unitedkingdom.html) or [PDF document](#).